Efficacy and safety of doripenem versus piperacillin ... | 合法藥品大搜索

由ARéa-Neto著作·2008·被引用131次—DoripenemwasclinicallyandmicrobiologicallyeffectiveinpatentswithNP,includingthosewithearly-onsetventilator-associatedpneumonia, ...

Objective: Doripenem is a new carbapenem that has broad-spectrum activity against bacterial pathogens commonly responsible for nosocomial pneumonia (NP). It has several advantages over currently available carbapenems and other classes of drugs used in this indication. This prospective, randomized, open-label, multicenter study was designed to establish whether doripenem was noninferior to piperacillin/tazobactam in NP.

Methods: Adults (n=448) with signs and symptoms of NP, including non-ventilated patients and those ventilated for <5 days, were stratified by ventilation mode, illness severity (Acute Physiology and Chronic Health Evaluation II score), and geographic region and then randomly allocated to treatment with doripenem 500 mg every 8 h by a 1-h intravenous (IV) infusion or ...